← Back to MiMOUD

Sources

Methamphetamine + MOUD: When One Treatment Is Working and Another Problem Isn't

  1. ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder.
    Clinical practice guideline. Journal of Addiction Medicine. 2024;18(1S Suppl 1):1–56. DOI: 10.1097/ADM.0000000000001299 — pubmed.ncbi.nlm.nih.gov/38669101
  2. SAMHSA — Low-Barrier Models of Care for Substance Use Disorders.
    Federal practice advisory PEP23-02-00-005 — library.samhsa.gov/.../advisory-low-barrier-models-of-care-pep23-02-00-005.pdf
  3. Tsui JI, et al. Association between methamphetamine use and retention among patients with opioid use disorders treated with buprenorphine.
    Prospective cohort. Journal of Substance Abuse Treatment. 2020;109:80–85. DOI: 10.1016/j.jsat.2019.10.005 — pubmed.ncbi.nlm.nih.gov/31810594
  4. Russell C, Law J, Imtiaz S, Rehm J, Le Foll B, Ali F. The impact of methamphetamine use on medications for opioid use disorder (MOUD) treatment retention: a scoping review.
    Addiction Science & Clinical Practice. 2023;18:48. DOI: 10.1186/s13722-023-00402-0 — pubmed.ncbi.nlm.nih.gov/37587456
  5. Kratina-Hathaway Z, et al. Methamphetamine use and illicit opioid use during buprenorphine treatment.
    Secondary analysis. Journal of Substance Use and Addiction Treatment. 2023;151:208934. DOI: 10.1016/j.josat.2022.208934 — pubmed.ncbi.nlm.nih.gov/37811395
  6. Edgerton R, et al. The impact of psychostimulant use on office based buprenorphine treatment retention.
    Observational low-threshold OBOT cohort. Harm Reduction Journal. 2025;22:51. DOI: 10.1186/s12954-025-01201-3 — pubmed.ncbi.nlm.nih.gov/40221764
  7. Bolívar HA, et al. Contingency Management for Patients Receiving Medication for Opioid Use Disorder: A Systematic Review and Meta-analysis.
    JAMA Psychiatry. 2021;78(10):1092–1102. DOI: 10.1001/jamapsychiatry.2021.1969 — pubmed.ncbi.nlm.nih.gov/34347030
  8. SAMHSA — Using SAMHSA Funds to Implement Evidence-Based Contingency Management Services.
    Federal advisory, January 2025. PEP24-06-001 — library.samhsa.gov/.../contingency-management-advisory-pep24-06-001.pdf
  9. Fredericksen RJ, et al. Motivation and context of concurrent stimulant and opioid use among persons who use drugs in the rural United States: a multi-site qualitative inquiry.
    Harm Reduction Journal. 2024;21:74. DOI: 10.1186/s12954-024-00986-z — pubmed.ncbi.nlm.nih.gov/38561753
  10. Trivedi MH, et al. Bupropion and Naltrexone in Methamphetamine Use Disorder (ADAPT-2).
    Multisite RCT. New England Journal of Medicine. 2021;384:140–153. DOI: 10.1056/NEJMoa2020214 — pubmed.ncbi.nlm.nih.gov/33497547
  11. Coffin PO, et al. Effects of Mirtazapine for Methamphetamine Use Disorder Among Cisgender Men and Transgender Women Who Have Sex With Men: A Placebo-Controlled Randomized Clinical Trial.
    JAMA Psychiatry. 2020;77(3):246–255. DOI: 10.1001/jamapsychiatry.2019.3655 — pubmed.ncbi.nlm.nih.gov/31825466